<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">39436440</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1613-7671</ISSN><JournalIssue CitedMedium="Internet"><Volume>136</Volume><Issue>21-22</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Wiener klinische Wochenschrift</Title><ISOAbbreviation>Wien Klin Wochenschr</ISOAbbreviation></Journal><ArticleTitle>A&#xa0;short story of long COVID.</ArticleTitle><Pagination><StartPage>587</StartPage><EndPage>589</EndPage><MedlinePgn>587-589</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00508-024-02453-y</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kundi</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Public Health, Department of Environmental Health, Medical University of Vienna, Kinderspitalgasse&#xa0;15, 1090, Vienna, Austria. michael.kundi@meduniwien.ac.at.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>Wien Klin Wochenschr</MedlineTA><NlmUniqueID>21620870R</NlmUniqueID><ISSNLinking>0043-5325</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39436440</ArticleId><ArticleId IdType="doi">10.1007/s00508-024-02453-y</ArticleId><ArticleId IdType="pii">10.1007/s00508-024-02453-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soriano&#xa0;JB, Murthy&#xa0;S, Marshall&#xa0;JC, Relan&#xa0;P, Diaz&#xa0;JV. A&#xa0;clinical case definition of post-COVID-19 condition by a&#xa0;Delphi consensus. Lancet Infect Dis. 2022;22(4):e102&#x2013;e7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec;&#xa0;A, Bernabei&#xa0;R, Landi&#xa0;F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId><ArticleId IdType="pmc">7349096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase&#xa0;E. Covid-19: what do we know about &#x201c;long covid&#x201d;? BMJ. 2020;370:m2815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m2815</ArticleId><ArticleId IdType="pubmed">32665317</ArticleId></ArticleIdList></Reference><Reference><Citation>Elneima O, Hurst JR, Echevarria C, Quint JK, Walker S, Siddiqui S, et&#xa0;al. Long-term impact of COVID-19 hospitalisation among individuals with pre-existing airway diseases in the UK: a&#xa0;multicentre, longitudinal cohort study&#x2014;PHOSP-COVID. ERJ Open Res. 2024;10(4).</Citation></Reference><Reference><Citation>Ghafari&#xa0;M, Hall&#xa0;M, Golubchik&#xa0;T, Ayoubkhani&#xa0;D, House&#xa0;T, MacIntyre-Cockett&#xa0;G, et&#xa0;al. Prevalence of persistent SARS-CoV&#x2011;2 in a&#xa0;large community surveillance study. Nature. 2024;626(8001):1094&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-024-07029-4</ArticleId><ArticleId IdType="pubmed">38383783</ArticleId><ArticleId IdType="pmc">10901734</ArticleId></ArticleIdList></Reference><Reference><Citation>Alipoor&#xa0;SD, Mirsaeidi&#xa0;M. SARS-CoV&#x2011;2 cell entry beyond the ACE2 receptor. Mol Biol Rep. 2022;49(11):10715&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-022-07700-x</ArticleId><ArticleId IdType="pubmed">35754059</ArticleId><ArticleId IdType="pmc">9244107</ArticleId></ArticleIdList></Reference><Reference><Citation>Donald J, Bilasy SE, Yang C, El-Shamy A. Exploring the complexities of long COVID. Viruses. 2024;16(7).</Citation></Reference><Reference><Citation>Vojdani A, Vojdani E, Saidara E, Maes M. Persistent SARS-coV&#x2011;2 infection, EBV, HHV&#x2011;6 and other factors may contribute to inflammation and autoimmunity in long COVID. Viruses. 2023;15(2).</Citation></Reference><Reference><Citation>Maes&#xa0;M, Almulla&#xa0;AF, Tang&#xa0;X, Stoyanova&#xa0;K, Vojdani&#xa0;A. From human herpes virus&#x2011;6 reactivation to autoimmune reactivity against tight junctions and neuronal antigens, to inflammation, depression, and chronic fatigue syndrome due to long COVID. J&#xa0;Med Virol. 2024;96(8):e29864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29864</ArticleId><ArticleId IdType="pubmed">39158051</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang&#xa0;EY, Mao&#xa0;T, Klein&#xa0;J, Dai&#xa0;Y, Huck&#xa0;JD, Jaycox&#xa0;JR, et&#xa0;al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Kratzer&#xa0;B, Gattinger&#xa0;P, Trapin&#xa0;D, Ettel&#xa0;P, K&#xf6;rm&#xf6;czi&#xa0;U, Rottal&#xa0;A, et&#xa0;al. Differential decline of SARS-CoV-2-specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID-19. Allergy. 2024;79(9):2482&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.16210</ArticleId><ArticleId IdType="pubmed">39003594</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang&#xa0;C, Hou&#xa0;Y, Schenck&#xa0;EJ, Xu&#xa0;Z, Zhang&#xa0;Y, Xu&#xa0;J, et&#xa0;al. Identification of risk factors of long COVID and predictive modeling in the RECOVER EHR cohorts. Commun Med. 2024;4(1):130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-024-00549-0</ArticleId><ArticleId IdType="pubmed">38992068</ArticleId><ArticleId IdType="pmc">11239808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg-Morris&#xa0;L, Leach&#xa0;S, Xu&#xa0;Y, Martikainen&#xa0;J, Santosa&#xa0;A, Gissl&#xe9;n&#xa0;M, et&#xa0;al. Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study. BMJ. 2023;383:e76990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2023-076990</ArticleId><ArticleId IdType="pubmed">37993131</ArticleId><ArticleId IdType="pmc">10666099</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra&#xa0;AR, Kobayashi&#xa0;T, Callado&#xa0;GY, Pardo&#xa0;I, Gutfreund&#xa0;MC, Hsieh&#xa0;MK, et&#xa0;al. The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: a&#xa0;systematic literature review and meta-analysis of the latest research. Antimicrob Steward Healthc Epidemiol. 2023;3(1):e168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ash.2023.447</ArticleId><ArticleId IdType="pubmed">38028898</ArticleId><ArticleId IdType="pmc">10644173</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie&#xa0;Y, Choi&#xa0;T, Al-Aly&#xa0;Z. Association of treatment with Nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023;183(6):554&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId><ArticleId IdType="pmc">10037200</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel&#xa0;JM, Pollack&#xa0;B, Spier&#xa0;E, McCorkell&#xa0;L, Jaudon&#xa0;TW, Fitzgerald&#xa0;M, et&#xa0;al. Designing and optimizing clinical trials for long COVID. Life Sci. 2024;355:122970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2024.122970</ArticleId><ArticleId IdType="pubmed">39142505</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>